Rib-X℠ is developing new antibiotics to provide superior coverage, safety and convenience for the treatment of serious and life-threatening infections. More

04.13.12 - Rib-X Pharmaceuticals Appoints Infectious Disease Expert and Former FDA Deputy Director Matthew Wikler, MD as Chief Development Officer  Read More

02.07.12 - Rib-X Pharmaceuticals Receives $3 Million Milestone Payment from Sanofi in the RX-04 Collaboration  Read More 

12.15.11 - Rib-X Reports Positive Top-Line Data from Phase 2b Study of Delafloxacin in Patients with Acute Bacterial Skin and Skin Structure Infections Read More